SOPHiA GENETICS (NASDAQ:SOPH) Upgraded at Zacks Research

Zacks Research upgraded shares of SOPHiA GENETICS (NASDAQ:SOPH) to a hold rating in a research report sent to investors on Tuesday morning,Zacks.com reports.

A number of other equities research analysts also recently weighed in on SOPH. BTIG Research reaffirmed a “buy” rating and issued a $8.00 target price on shares of SOPHiA GENETICS in a report on Monday, June 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Finally, HC Wainwright initiated coverage on SOPHiA GENETICS in a research report on Monday. They set a “buy” rating and a $12.00 price objective for the company. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $9.00.

SOPHiA GENETICS Stock Performance

Shares of SOPHiA GENETICS stock opened at $6.05 on Tuesday. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05. The company has a market cap of $507.53 million, a PE ratio of -11.63 and a beta of 0.96. The company has a 50 day moving average of $5.36 and a 200-day moving average of $5.07. SOPHiA GENETICS has a 1-year low of $2.92 and a 1-year high of $6.77.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The firm had revenue of $21.69 million during the quarter, compared to the consensus estimate of $20.40 million. As a group, equities research analysts forecast that SOPHiA GENETICS will post -0.58 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other SOPHiA GENETICS news, CEO Ross Muken sold 9,838 shares of the business’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $5.22, for a total transaction of $51,354.36. Following the sale, the chief executive officer owned 670,651 shares of the company’s stock, valued at approximately $3,500,798.22. The trade was a 1.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CTO Abhimanyu Verma sold 6,944 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $5.51, for a total transaction of $38,261.44. Following the transaction, the chief technology officer owned 197,456 shares of the company’s stock, valued at $1,087,982.56. This trade represents a 3.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 176,711 shares of company stock worth $959,913 over the last 90 days. Insiders own 4.88% of the company’s stock.

Institutional Investors Weigh In On SOPHiA GENETICS

Several hedge funds have recently modified their holdings of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after purchasing an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC boosted its stake in shares of SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after purchasing an additional 1,481,636 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares in the last quarter. Archon Capital Management LLC grew its holdings in shares of SOPHiA GENETICS by 3.4% during the fourth quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock worth $2,061,000 after purchasing an additional 14,342 shares during the last quarter. Finally, Hodges Capital Management Inc. bought a new stake in shares of SOPHiA GENETICS during the first quarter worth about $2,157,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

More SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $12 price target, suggesting meaningful upside from current levels if SOPHiA GENETICS can execute on its growth plan.
• Positive Sentiment: Longer-term HC Wainwright estimates turn positive, with FY2028, FY2029, and FY2030 forecast to move into profitability, which may support the stock’s long-term valuation.
• Neutral Sentiment: Zacks Research upgraded SOPHiA GENETICS to Hold, a signal that sentiment is improving somewhat but not enough to indicate a clear buy case.
• Negative Sentiment: HC Wainwright’s near-term EPS estimates remain negative through FY2026 and FY2027, reinforcing investor concern that SOPHiA GENETICS may need more time before sustained earnings improvement.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.